Literature DB >> 12668866

Prolactin regulation by heparin-binding growth factors expressed in mouse pituitary cell lines.

Robert Hnasko1, Nira Ben-Jonathan.   

Abstract

Prolactin (PRL) secretion is regulated by both inhibitory and stimulatory factors. Dopamine is the primary inhibitor, but multiple factors stimulate PRL gene expression and release. These can be divided into two categories: those that rapidly stimulate PRL release and those that induce the PRL gene followed by increased release. The pituitary intermediate lobe (IL) contains a PRL-releasing factor (PRF) that rapidly stimulates PRL release. From a mouse IL tumor, we established a non-melanotroph cell line, mIL5, which secretes a factor that stimulated PRL gene expression and release in vitro. This PRF activity did not rapidly stimulate PRL release and bound to heparin. Our objective was to examine the regulation of PRL by heparin-binding proteins and characterize the PRF activity produced by mIL5 cells. PRL gene expression and release was determined using GH3 cells, stably transfected with a PRL promoter/luciferase reporter (GH(3)/luc). After screening mIL5 cells by reverse transcriptase polymerase chain reaction, we found that they expressed two heparin-binding growth factors basic fibroblast growth factor (FGF-2) and heparin-binding epidermal growth factor (HB-EGF) which were considered strong candidates for PRL transcriptional regulatory activity. To determine whether the activity produced by mIL5 cells is attributed to FGF-2 or HB-EGF, three approaches were used: heparin-affinity chromatography, Western blotting, and immunoneutralization. The PRF activity in conditioned media eluted from heparin with 1 M NaCl whereas both FGF- 2 and HB-EGF eluted with >1 M NaCl. Neither growth factor was detectable in mIL5 cells by Western blotting. Antibodies directed against FGF-2 and HB-EGF, alone or together, did not abolish this activity from mIL5 cells. In conclusion, FGF-2 and HB-EGF are potent stimulators of PRL gene expression and release but do not account for most of the endogenous PRL gene activity in mIL5 cells. The distinct heparin-binding factor that stimulates PRL gene transcription remains to be identified.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12668866     DOI: 10.1385/ENDO:20:1-2:35

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  33 in total

1.  Rapid augmentation of prolactin cell number and secretory capacity by an estrogen-induced factor released from the neurointermediate lobe.

Authors:  E Ellerkmann; G M Nagy; L S Frawley
Journal:  Endocrinology       Date:  1991-08       Impact factor: 4.736

2.  Acute effect of basic fibroblast growth factor on secretion of prolactin as assessed by the reverse hemolytic plaque assay.

Authors:  G H Larson; R D Koos; M A Sortino; P M Wise
Journal:  Endocrinology       Date:  1990-02       Impact factor: 4.736

3.  Basic and acidic fibroblast growth factor increase prolactin mRNA in a dose-dependent and specific manner in GH3 cells.

Authors:  F Mallo; E Wilson; C B Whorwood; S Singh; M C Sheppard
Journal:  Mol Cell Endocrinol       Date:  1995-10-30       Impact factor: 4.102

4.  A secreted FGF-binding protein can serve as the angiogenic switch in human cancer.

Authors:  F Czubayko; E D Liaudet-Coopman; A Aigner; A T Tuveson; G J Berchem; A Wellstein
Journal:  Nat Med       Date:  1997-10       Impact factor: 53.440

5.  Adenovirus-mediated retinoblastoma gene therapy suppresses spontaneous pituitary melanotroph tumors in Rb+/- mice.

Authors:  D J Riley; A Y Nikitin; W H Lee
Journal:  Nat Med       Date:  1996-12       Impact factor: 53.440

Review 6.  Follistatin: a multifunctional regulatory protein.

Authors:  D J Phillips; D M de Kretser
Journal:  Front Neuroendocrinol       Date:  1998-10       Impact factor: 8.606

7.  Stimulation of lactotrope differentiation in vitro by fibroblast growth factor.

Authors:  T E Porter; C D Wiles; L S Frawley
Journal:  Endocrinology       Date:  1994-01       Impact factor: 4.736

8.  Stimulation of hypothalamic prolactin release by veratridine and angiotensin II in the female rat: effect of ovariectomy and estradiol administration.

Authors:  W J DeVito; S Stone; C Avakian
Journal:  Neuroendocrinology       Date:  1991-10       Impact factor: 4.914

9.  Histological evaluation of the dopaminergic regulation of proopiomelanocortin gene expression in the intermediate lobe of the rat pituitary, involving in situ hybridization and [3H]thymidine uptake measurement.

Authors:  B M Chronwall; W R Millington; W S Griffin; J R Unnerstall; T L O'Donohue
Journal:  Endocrinology       Date:  1987-03       Impact factor: 4.736

10.  Posterior pituitary lobectomy abolishes the suckling-induced rise in prolactin (PRL): evidence for a PRL-releasing factor in the posterior pituitary.

Authors:  I Murai; N Ben-Jonathan
Journal:  Endocrinology       Date:  1987-07       Impact factor: 4.736

View more
  2 in total

1.  Heparin-binding epidermal growth factor and its receptors mediate decidualization and potentiate survival of human endometrial stromal cells.

Authors:  Katya Chobotova; Natalia Karpovich; Janet Carver; Sanjiv Manek; William J Gullick; David H Barlow; Helen J Mardon
Journal:  J Clin Endocrinol Metab       Date:  2004-11-23       Impact factor: 5.958

2.  Heparin increases prolactin and modifies the effects of fgf-2 upon prolactin accumulation in pituitary primary cultures.

Authors:  Carlos Spuch; Yolanda Diz-Chaves; Diego Pérez-Tilve; Federico Mallo
Journal:  Endocrine       Date:  2004-07       Impact factor: 3.633

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.